Novavax (NVAX) PT Lowered to $235 at Jefferies After Rollout Delay Concedes First Mover Advantage
Get Alerts NVAX Hot Sheet
Price: $3.95 -4.82%
Rating Summary:
9 Buy, 4 Hold, 4 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
9 Buy, 4 Hold, 4 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Jefferies analyst Kelechi Chikere lowered the price target on Novavax (NASDAQ: NVAX) to $235.00 (from $310.00) after the company reported Q1 results and updated timelines for its CV-19 vaccine.
The analyst reiterated a Buy rating expecting "a measured rollout in 2021 with a large pickup in the first half of 2022. Investors will be disappointed as it means sales in 2021 are likely to be modest, MRNA vaccines have more time to gain mindshare and more vaccines potentially enter the mkt. While recognizing the NT headwinds, we remain (+) on the mid to long-term outlook for NVAX's CV-19 vaccine prgm."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Keurig Dr Pepper (KDP) PT Raised to $39 at Jefferies
- META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
- Comcast Corp (CMCSA) PT Lowered to $48 at Pivotal Research
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!